The use of photodynamic therapy for diseases of the esophagus

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 27, Issue 1, 2008, Pages 5-21

  Gross, Seth A ^a   Wolfsen, Herbert C ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Aminolevulinic acid; Barrett's esophagus; Benzoporphyrin; Esophageal cancer; Motoxafin lutetium; Pheophorbides; Phthalocyanine; Porfimer sodium; Talaporfin; Temoporfin

Indexed keywords

3 TETRAHYDROXYPHENYLCHLORINE; ALUMINUM DISULPHONATED PHTHALOCYANINE; AMINOLEVULINIC ACID; BENZOPORPHYRIN DERIVATIVE; CHLORINE DERIVATIVE; CHLOROALUMINUM PHTHALOCYANINE TETRASULFONATE; FOTOLON; HEMATOPORPHYRIN DERIVATIVE; HEMPORFIN; LEMUTEPORFIN; LUTETIUM TEXAPHYRIN; MOTOXAFIN LUTETIUM; OMEPRAZOLE; PHEOPHORBIDE; PHOTOCHLOR; PHOTOFRIN; PHOTOGEM; PHOTOSAN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE DERIVATIVE; PORPHYRIN DERIVATIVE; PREDNISONE; PROGESTERONE; PURPURIN DERIVATIVE; SILICON PHTHALOCYANINE; TALAPORFIN; TEMOPORFIN; UNCLASSIFIED DRUG;

BARRETT ESOPHAGUS; CANCER THERAPY; CLINICAL TRIAL; DOSIMETRY; DRUG EFFECT; DRUG EFFICACY; ESOPHAGOSCOPY; ESOPHAGUS CARCINOMA; ESOPHAGUS DISEASE; HUMAN; IRRADIATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 41949105953     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvironPatholToxicolOncol.v27.i1.20     Document Type: Review

References (130)

1. Peng Q. Editorial: photodynamic therapy and detection. J Environ Pathol Toxicol Oncol. 2006;25(1-2):1-5.
2. McCaughan JS Jr, Ellison EC, Guy JT, Hicks WJ, Jones JJ, Laufman LR, May E, Nims TA, Spiridonidis CH, Williams TE. Photodynamic therapy for esophageal malignancy: a prospective twelve-year study. Ann Thorac Surg. 1996;62(4):1005-9.
3. Litle VR, Luketich JD, Christie NA, Buenaventura PO, Alvelo-Rivera M, McCaughan JS, Nguyen NT, Fernando HC. Photodynamic therapy as palliation for esophageal cancer: experience in 215 patients. Ann Thorac Surg. 2003;76(5):1687-92; discussion92-3.
4. Lightdale CJ, Heier SK, Marcon NE, McCaughan JS Jr, Gerdes H, Overholt BF, Sivak MV, Jr., Stiegmann GV, Nava HR. Photodynamic therapy with porfi mer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc. 1995;42(6):507-12.
5. Overholt BF, Lightdale CJ, Wang KK, Canto M. International multicenter partially binded randomized study of the efficacy of photodynamic therapy (PDT) using portimer sodium (POR) for ablation of high-grade dysplasia (HGD) in Barrett's esophagus (BE) and results of 24 month follow up. Gastroenterology. 2003(124 Suppl 1):A20.
6. Overholt BF, Wang KK, Burdick JS, Lightdale CJ, Kimmey M, Nava HR, Sivak MV Jr, Nishioka N, Barr H, Marcon N, Pedrosa M, Bronner MP, Grace M, Depot M. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's highgrade dysplasia. Gastrointest Endosc. 2007 Jul 20;66:460-8.
7. Overholt BF, Lightdale CJ, Wang KK, Canto MI, Burdick S, Haggitt RC, Bronner MP, Taylor SL, Grace MG, Depot M. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005 Oct;62(4):488-98.
8. Wolfsen HC. Endoluminal therapy for Barrett's esophagus. Gastrointest Endosc Clin N Am. 2007 Jan;17(1):59-82, vi-vii.
9. Wolfsen HC. Present status of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. J Clin Gastroenterol. 2005 Mar;39(3):189-202.
10. Wolfsen HC. Carpe luz-seize the light: endoprevention of esophageal adenocarcinoma when using photodynamic therapy with porfimer sodium. Gastrointest Endosc. 2005 Oct;62(4):499-503.
11. Wolfsen HC. Endoprevention of esophageal cancer: endoscopic ablation of Barrett's metaplasia and dysplasia. Expert Rev Med Devices. 2005 Nov;2(6):713-23.
12. Prosst RL, Wolfsen HC, Gahlen J. Photodynamic therapy for esophageal diseases: a clinical update. Endoscopy. 2003 Dec;35(12):1059-68.
13. Wang KK. Current status of photodynamic therapy of Barrett's esophagus. Gastrointest Endosc. 1999;49(3 Pt 2):S20-3.
14. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc. 2003 Aug;58(2):183-8.
15. Sampliner RE. Prevention of adenocarcinoma by reversing Barrett's esophagus with mucosal ablation. World J Surg. 2003 Sep;27(9):1026-9.
16. Perry Y, Epperly MW, Fernando HC, Klein E, Finkelstein S, Greenberger JS, Luketich JD. Photodynamic therapy induced esophageal stricture - an animal model: from mouse to pig. J Surg Res. 2005 Jan;123(1):67-74.
17. Cramers P, Ruevekamp M, Oppelaar H, Dalesio O, Baas P, Stewart FA. Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br J Cancer. 2003 Jan 27;88(2):283-90.
18. Wagnieres G, Hadjur C, Grosjean P, Braichotte D, Savary JF, Monnier P, van den Bergh H. Clinical evaluation of the cutaneous phototoxicity of 5,10,15,20-tetra(m-hydroxyphenyl)chlorin. Photochem Photobiol. 1998 Sep;68(3):382-7.
19. Barr H, Kendall C, Stone N. Photodynamic therapy for esophageal cancer: a useful and realistic option. Technol Cancer Res Treat. 2003 Feb;2(1):65-76.
20. Bown SG, Rogowska AZ. New photosensitizers for photodynamic therapy in gastroenterology. Can J Gastroenterol. 1999;13(5):389-92.
21. Gray J, Fullarton G. The current role of photodynamic therapy in oesophageal dysplasia and cancer. Photodiag Photodyn Ther. 2007;4(3):151-9.
22. Falk GW. Barrett's esophagus. Gastroenterology. 2002 May;122(6):1569-91.
23. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology. 1990;99(4):918-22.
24. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med. 1985;313(14):857-9.
25. Reid BJ. Barrett's esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am. 1991;20(4):817-34.
26. Ward EM, Wolfsen HC, Achem SR, Loeb DS, Krishna M, Hemminger LL, DeVault KR. Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of reflux symptoms. Am J Gastroenterol. 2006 Jan;101(1):12-7.
27. Conio M, Lapertosa G, Blanchi S, Filiberti R. Barrett's esophagus: an update. Crit Rev Oncol Hematol. 2003;46(2):187-206.
28. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998 Nov 15;83(10):2049-53.
29. Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Toledano AY, Shyr Y, Washington K. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32(4):368-78.
30. Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, Anderson MA, Petterson TM, Burgart LJ. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120(7):1630-9.
31. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, Seidel UJ, Sonnenberg A. Longterm nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology. 2001;120(7):1607-19.
32. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000 Jul;95(7):1669-76.
33. Weston AP, Sharma P. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma. Am J Gastroenterol. 2002 Dec;97(12):2998-3006.
34. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology. 1989;96(5 Pt 1):1249-56.
35. Zaninotto G, Minnei F, Guirroli E, Ceolin M, Battaglia G, Bellumat A, Betetto G, Bozzola L, Cassaro M, Cataudella G, Dal Bo N, Farinati F, Florea G, Furlanetto A, Galliani E, Germana B, Guerini A, Macri E, Marcon V, Mastropaolo G, Meggio A, Miori G, Morelli L, Murer B, Norberto L, Togni R, Valiante F, Rugge M. The Veneto Region's Barrett's Oesophagus Registry: aims, methods, preliminary results. Dig Liver Dis. 2007 Jan;39(1):18-25.
36. Canto MI. Vital staining and Barrett's esophagus. Gastrointest Endosc. 1999 Mar;49(3 Pt 2):S12-6.
37. Canto MI, Setrakian S, Willis J, Chak A, Petras R, Powe NR, Sivak MV, Jr. Methylene blue-directed biopsies improve detection of intestinal metaplasia and dysplasia in Barrett's esophagus. Gastrointest Endosc. 2000 May;51(5):560-8.
38. Wo JM, Ray MB, Mayfield-Stokes S, Al-Sabbagh G, Gebrail F, Slone SP, Wilson MA. Comparison of methylene blue-directed biopsies and conventional biopsies in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a preliminary study. Gastrointest Endosc. 2001 Sep;54(3):294-301.
39. Dave U, Shousha S, Westaby D. Methylene blue staining: is it really useful in Barrett's esophagus? Gastrointest Endosc. 2001 Mar;53(3):333-5.
40. Sharma P, Weston AP, Topalovski M, Cherian R, Bhattacharyya A, Sampliner RE. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's oesophagus. Gut. 2003 Jan;52(1):24-7.
41. Curvers W, Singh R, Wong Kee Song L, Wolfsen H, Ragunath K, Wang K, Wallace M, Fockens P, Bergman J. Endoscopic tri-modal imaging for detection of early neoplasia in Barrett's oesophagus; A multicentre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Endoscopy. 2007;39(Suppl 1):A1.
42. Wolfsen HC, Crook JE, Krishna M, Achem SR, DeVault KR, Bouras EP, Loeb DS, Stark ME, Woodward TA, Hemminger LL, Cayer FK, Wallace MB. Prospective, controlled tandem endoscopy study of narrow band imaging for the detection of dysplasia in Barrett's esophagus. Gut. 2007;56(Suppl III):A47.
43. Tokar JL, Haluszka O, Weinberg DS. Endoscopic therapy of dysplasia and early-stage cancers of the esophagus. Semin Radiat Oncol. 2007 Jan;17(1):10-21.
44. Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg. 2002;20(1):3-7.
45. Allison SP, Lobo DN. Fluid and electrolytes in the elderly. Curr Opin Clin Nutr Metab Care. 2004 Jan;7(1):27-33.
46. Qiang YG, Zhang XP, Li J, Huang Z. Photodynamic therapy for malignant and non-malignant diseases: clinical investigation and application. Chin Med J (Engl). 2006 May 20;119(10):845-57.
47. Ackroyd R, Kelty C, Brown N, Reed M. The history of photodetection and photodynamic therapy. Photochem Photobiol. 2001 Nov;74(5):656-69.
48. Bellnier DA, Greco WR, Loewen GM, Nava H, Oseroff AR, Pandey RK, Tsuchida T, Dougherty TJ. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients. Cancer Res. 2003 Apr 15;63(8):1806-13.
49. Wolfsen HC, Hemminger LL, Raimondo M, Woodward TA. Photodynamic therapy and endoscopic mucosal resection for Barrett's dysplasia and early esophageal adenocarcinoma. South Med J. 2004 Sep;97(9):827-30.
50. Soetikno RM, Gotoda T, Nakanishi Y, Soehendra N. Endoscopic mucosal resection. Gastrointest Endosc. 2003;57(4):567-79.
51. Ell C, May A, Gossner L, Pech O, Gunter E, Mayer G, Henrich R, Vieth M, Muller H, Seitz G, Stolte M. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2000;118(4):670-7.
52. Seewald S, Akaraviputh T, Seitz U, Brand B, Groth S, Mendoza G, He X, Thonke F, Stolte M, Schroeder S, Soehendra N. Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc. 2003 Jun;57(7):854-9.
53. Conio M, Cameron AJ, Chak A, Blanchi S, Filiberti R. Endoscopic treatment of high-grade dysplasia and early cancer in Barrett's oesophagus. Lancet Oncol. 2005 May;6(5):311-21.
54. Mino-Kenudson M, Brugge WR, Puricelli WP, Nakatsuka LN, Nishioka NS, Zukerberg LR, Misdraji J, Lauwers GY. Management of superficial Barrett's epithelium-related neoplasms by endoscopic mucosal resection: clinicopathologic analysis of 27 cases. Am J Surg Pathol. 2005 May;29(5):680-6.
55. May A, Gossner L, Behrens A, Kohnen R, Vieth M, Stolte M, Ell C. A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc. 2003 Aug;58(2):167-75.
56. Rosch T, Sarbia M, Schumacher B, Deinert K, Frimberger E, Toermer T, Stolte M, Neuhaus H. Attempted endoscopic en bloc resection of mucosal and submucosal tumors using insulated-tip knives: a pilot series. Endoscopy. 2004 Sep;36(9):788-801.
57. May A, Gossner L, Pech O, Fritz A, Gunter E, Mayer G, Muller H, Seitz G, Vieth M, Stolte M, Ell C. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol. 2002 Oct;14(10):1085-91.
58. Giovannini M, Bories E, Pesenti C, Moutardier V, Monges G, Danisi C, Lelong B, Delpero JR. Circumferential endoscopic mucosal resection in Barrett's esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients. Endoscopy. 2004 Sep;36(9):782-7.
59. Buttar NS, Wang KK, Lutzke LS, Krishnadath KK, Anderson MA. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc. 2001;54(6):682-8.
60. Nijhawan PK, Wang KK. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointest Endosc Clin N Am. 2000;10(3):421-37.
61. Noguchi H, Naomoto Y, Kondo H, Haisa M, Yamatsuji T, Shigemitsu K, Aoki H, Isozaki H, Tanaka N. Evaluation of endoscopic mucosal resection for superfi cial esophageal carcinoma. Surg Laparosc Endosc Percutan Tech. 2000 Dec;10(6):343-50.
62. Takeshita K, Tani M, Inoue H, Saeki I, Hayashi S, Honda T, Kando F, Saito N, Endo M. Endoscopic treatment of early oesophageal or gastric cancer. Gut. 1997;40(1):123-7.
63. Rajan E, Gostout CJ, Feitoza AB, Leontovich ON, Herman LJ, Burgart LJ, Chung S, Cotton PB, Hawes RH, Kalloo AN, Kantsevoy SV, Pasricha PJ. Widespread EMR: a new technique for removal of large areas of mucosa. Gastrointest Endosc. 2004 Oct;60(4):623-7.
64. Overholt B, Panjehpour M, Tefftellar E, Rose M. Photodynamic therapy for treatment of early adenocarcinoma in Barrett's esophagus. Gastrointest Endosc. 1993;39(1):73-6.
65. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc. 1999;49(1):1-7.
66. Wang KK, Kim JY. Photodynamic therapy in Barrett's esophagus. Gastrointest Endosc Clin N Am. 2003 Jul;13(3):483-9, vii.
67. Wolfsen HC, Woodward TA, Raimondo M. Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma. Mayo Clin Proc. 2002;77(11):1176-81.
68. Wolfsen HC, Hemminger LL, Wallace MB, Devault KR. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1 125-31.
69. Wang KK, Wong Kee Song LM, Buttar NS, Papenfuss S, Lutzke L. Barrett's esophagus after photodynamic therapy: risk of cancer development during long term follow up [abstract]. Gastroenterology. 2004;126(suppl 2):A50.
70. Wolfsen HC, Hemminger LL. Photodynamic therapy for dysplastic Barrett's esophagus and mucosal adenocarcinoma [abstract]. Gastrointest Endosc. 2004;59(5):AB251.
71. Ukleja A, Scolapio JS, Wolfsen HC. Endoscopic ultrasonography (EUS) and endoscopic mucosal resection (EMR) for staging and treatment of high-grade dysplasia (HGD) and early adenocarcinoma (EAC) in Barrett's esophagus (BE) [abstract]. Gastrotenterology. 1999;116:A582.
72. Nijhawan PK, Wolfsen HC, Wang KK, Buttar NS, Lutzke L, Anderson M. Cutaneous photosensitivity after photodynamic therapy: Is it really more common in sunny climates? [abstract]. Gastroenterology. 2000;118(4):A227.
73. Panjehpour M, Overholt BF, Haydek JM, Lee SG. Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation. Am J Gastroenterol. 2000;95(9):2177-84.
74. Panjehpour M, Overholt BF, Phan MN, Haydek JM. Optimization of light dosimetry for photodynamic therapy of Barrett's esophagus: efficacy vs. incidence of stricture after treatment. Gastrointest Endosc. 2005 Jan;61(1):13-8.
75. Pacifico RJ, Wang KK, Wong Kee Song LM, Buttar NS, Lutzke LS. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol. 2003;1(4):252-7.
76. Prasad GA, Wang KK, Buttar NS, Wongkeesong LM, Krishnadath KK, Nichols FC III, Lutzke LS, Borkenhagen LS. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2007 Apr;132(4):1226-33.
77. Foroulis CN, Thorpe JA. Photodynamic therapy (PDT) in Barrett's esophagus with dysplasia or early cancer. Eur J Cardiothorac Surg. 2006 Jan;29(1):30-4.
78. Keeley SB, Pennathur A, Gooding W, Landreneau RJ, Christie NA, Luketich J. Photodynamic therapy with curative intent for Barrett's esophagus with high grade dysplasia and superficial esophageal cancer. Ann Surg Oncol. 2007 Aug;14(8):2406-10.
79. Hemminger LL, Wolfsen HC. Photodynamic therapy for Barrett's esophagus and high grade dysplasia: results of a patient satisfaction survey. Gastroenterol Nurs. 2002 Jul-Aug;25(4):139-41.
80. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Dig Dis Sci. 2003 Jul;48(7):1273-83.
81. Wolfsen HC, Hemminger LL, DeVault KR. Barrett's dysplasia and mucosal carcinoma patients referred for photodynamic therapy - do they come from surveillance programs? [abstract]. Gastrointest Endosc. 2004;59(5):AB265.
82. Andrejevic-Blant S, Hadjur C, Ballini JP, Wagnieres G, Fontolliet C, van den Bergh H, Monnier P. Photodynamic therapy of early squamous cell carcinoma with tetra(m-hydroxyphenyl)chlorin: optimal druglight interval. Br J Cancer. 1997;76(8):1021-8.
83. Andrejevic Blant S, Grosjean P, Ballini JP, Wagnieres G, van den Bergh H, Fontolliet C, Monnier P. Localization of tetra(m-hydroxyphenyl)chlorin (Foscan) in human healthy tissues and squamous cell carcinomas of the upper aero-digestive tract, the esophagus and the bronchi: a fluorescence microscopy study. J Photochem Photobiol B. 2001 Aug 15;61(1-2):1-9.
84. Gossner L, May A, Sroka R, Ell C. A new long-range through-the-scope balloon applicator for photodynamic therapy in the esophagus and cardia. Endoscopy. 1999;31(5):370-6.
85. Gossner L, May A, Sroka R, Stolte M, Hahn EG, Ell C. Photodynamic destruction of high grade dysplasia and early carcinoma of the esophagus after the oral administration of 5-aminolevulinic acid. Cancer. 1999;86(10):1921-8.
86. Javaid B, Watt P, Krasner N. Photodynamic therapy (PDT) for oesophageal dysplasia and early carcinoma with mTHPC (m-tetrahydroxyphenyl chlorin): a preliminary study. Lasers Med Sci. 2002;17(1):51-6.
87. Etienne J, Dorme N, Bourg-Heckly G, Raimbert P, Flijou JF. Photodynamic therapy with green light and m-tetrahydroxyphenyl chlorin for intramucosal adenocarcinoma and high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc. 2004 Jun;59(7):880-9.
88. Lovat LB, Jamieson NF, Novelli MR, Mosse CA, Selvasekar C, Mackenzie GD, Thorpe SM, Bown SG. Photodynamic therapy with m-tetrahydroxyphenyl chlorin for high-grade dysplasia and early cancer in Barrett's columnar lined esophagus. Gastrointest Endosc. 2005 Oct;62(4):617-23.
89. Peng Q, Warloe T, Moan J, Godal A, Apricena F, Giercksky KE, Nesland JM. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts. Cancer Res. 2001 Aug 1;61(15):5824-32.
90. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE, Nesland JM. 5-aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer. 1997;79(12):2282-308.
91. Godal A, Nilsen NO, Klaveness J, Branden JE, Nesland JM, Peng Q. New derivatives of 5-aminolevulinic acid for photodynamic therapy: chemical synthesis and porphyrin production in in vitro and in vivo biological systems. J Environ Pathol Toxicol Oncol. 2006;25(1-2):109-26.
92. Bedwell J, MacRobert AJ, Phillips D, Bown SG. Fluorescence distribution and photodynamic effect of ALA-induced PP IX in the DMH rat colonic tumour model. Br J Cancer. 1992 Jun;65(6):818-24.
93. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B. 1992 Jul 30;14(4):275-92.
94. Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol. 1997 Feb;65(2):235-51.
95. Webber J, Kessel D, Fromm D. Side effects and photosensitization of human tissues after aminolevulinic acid. J Surg Res. 1997 Feb 15;68(1):31-7.
96. Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Marcus SL, Stoddard CJ, Johnson AG, Reed MW. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut. 2000;47(5):612-7.
97. Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Stoddard CJ, Reed MW. Aminolevulinic acid-induced photodynamic therapy: safe and effective ablation of dysplasia in Barrett's esophagus. Dis Esophagus. 2000;13(1):18-22.
98. Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn EG, Ell C. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology. 1998;114(3):448-55.
99. Barr H, Shepherd NA, Dix A, Roberts DJ, Tan WC, Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet. 1996;348(9027):584-5.
100. Orth K, Stanescu A, Ruck A, Russ D, Beger HG. Photodynamic ablation and argon-plasma coagulation of premalignant and early-stage malignant lesions of the oesophagus - an alternative to surgery? Chirurg. 1999;70(4):431-8.
101. Pech O, Gossner L, May A, Stolte M, Ell C. Long term results of PDT for early neoplasia in Barrett's esophagus. Gastrointest Endosc. 2004;59:W1567.
102. Guelrud M, Herrera I, Essenfeld H, Castro J. Enhanced magnification endoscopy: a new technique to identify specialized intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc. 2001 May;53(6):559-65.
103. Behrens A, May A, Gossner L, Gunter E, Pech O, Vieth M, Stolte M, Seitz G, Ell C. Curative treatment for high-grade intraepithelial neoplasia in Barrett's esophagus. Endoscopy. 2005 Oct;37(10):999-1005.
104. May A, Gossner L, Pech O, Muller H, Vieth M, Stolte M, Ell C. Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE): curative treatment using local endoscopic treatment techniques. Endoscopy. 2002;34(8):604-10.
105. Sylantiev C, Schoenfeld N, Mamet R, Groozman GB, Drory VE. Acute neuropathy mimicking porphyria induced by aminolevulinic acid during photodynamic therapy. Muscle Nerve. 2005 Mar;31(3):390-3.
106. Siersema PD. Photodynamic therapy for Barrett's esophagus: not yet ready for the premier league of endoscopic interventions. Gastrointest Endosc. 2005 Oct;62(4):503-7.
107. Ortner MA, Zumbusch K, Liebetruth J, Ebert B, Fleige B, Dietel M, Lochs H. Is topical delta-aminolevulinic acid adequate for photodynamic therapy in Barrett's esophagus? A pilot study. Endoscopy. 2002;34(8):611-6.
108. Ragunath K, Krasner N, Raman VS, Haqqani MT, Phillips CJ, Cheung I. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol. 2005 Jul;40(7):750-8.
109. Kelty CJ, Ackroyd R, Brown NJ, Brown SB, Reed MW. Comparison of high- vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett's esophagus. Surg Endosc. 2004 Mar;18(3):452-8.
110. Kelty CJ, Ackroyd R, Brown NJ, Stephenson TJ, Stoddard CJ, Reed MW. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther. 2004 Dec;20(11-12):1289-96.
111. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Haringsma J, van de Vrie W, Grool TE, van Veen RL, Sterenborg HJ, Kuipers EJ. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut. 2004 Jun;53(6):785-90.
112. Peters F, Kara M, Rosmolen W, Aalders M, Ten Kate F, Krishnadath K, van Lanschot J, Fockens P, Bergman J. Poor results of 5-aminolevulinic acid-photodynamic therapy for residual high-grade dysplasia and early cancer in Barrett esophagus after endoscopic resection. Endoscopy. 2005 May;37(5):418-24.
113. Mackenzie GD, Jamieson NF, Novelli MR, Mosse CA, Clark BR, Thorpe SM, Bown SG, Lovat LB. How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett's esophagus. Lasers Med Sci. 2007 Jul 3.
114. Mackenzie G, Selvasekar C, Jamieson N, Mosse C, Thorpe S, Novelli M, Bown S, Lovat L. Low incidence of esophageal adenocarcinoma following optimal regimen of ALA PDT for high grade dysplasia in Barrett's esophagus [abstract]. Gastrointest Endosc. 2007;65(5):AB132.
115. Boere IA, Robinson DJ, de Bruijn HS, van den Boogert J, Tilanus HW, Sterenborg HJ, de Bruin RW. Monitoring in situ dosimetry and protoporphyrin IX fluorescence photobleaching in the normal rat esophagus during 5-aminolevulinic acid photodynamic therapy. Photochem Photobiol. 2003 Sep;78(3):271-7.
116. Cheung R, Solonenko M, Busch TM, Del Piero F, Putt ME, Hahn SM, Yodh AG. Correlation of in vivo photosensitizer fluorescence and photodynamic-therapy- induced depth of necrosis in a murine tumor model. J Biomed Opt. 2003;8(2):248-52.
117. Radu A, Conde R, Fontolliet C, Wagnieres G, Van den Bergh H, Monnier P. Mucosal ablation with photodynamic therapy in the esophagus: optimization of light dosimetry in the sheep model. Gastrointest Endosc. 2003;57(7):897-905.
118. van den Bergh H. On the evolution of some endoscopic light delivery systems for photodynamic therapy. Endoscopy. 1998;30(4):392-407.
119. Panjehpour M, Overholt BF, Haydek JM. Light sources and delivery devices for photodynamic therapy in the gastrointestinal tract. Gastrointest Endosc Clin N Am. 2000;10(3):513-32.
120. Overholt BF, Panjehpour M, DeNovo RC, Peterson MG, Jenkins C. Balloon photodynamic therapy of esophageal cancer: effect of increasing balloon size. Lasers Surg Med. 1996;18(3):248-52.
121. Prasad GA, Wang KK, Buttar NS, Wongkeesong LM, Lutzke LS, Borkenhagen LS. Predictors of stricture formation after photodynamic therapy for highgrade dysplasia in Barrett's esophagus. Gastrointest Endosc. 2007 Jan;65(1):60-6.
122. Stepinac T, Grosjean P, Woodtli A, Monnier P, van den Bergh H, Wagnieres G. Optimization of the diameter of a radial irradiation device for photodynamic therapy in the esophagus. Endoscopy. 2002;34(5):411-5.
123. Braichotte DR, Savary JF, Monnier P, van den Bergh HE. Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy. Lasers Surg Med. 1996;19(3):340-6.
124. Zellweger M, Grosjean P, Monnier P, van den Bergh H, Wagnieres G. Stability of the fluorescence measurement of Foscan in the normal human oral cavity as an indicator of its content in early cancers of the esophagus and the bronchi. Photochem Photobiol. 1999;69(5):605-10.
125. Standish BA, Yang VX, Munce NR, Wong Kee Song LM, Gardiner G, Lin A, Mao YI, Vitkin A, Marcon NE, Wilson BC. Doppler optical coherence tomography monitoring of microvascular tissue response during photodynamic therapy in an animal model of Barrett's esophagus. Gastrointest Endosc. 2007 Aug;66(2):326-33.
126. Chen W, Huang Z. Biophotonics and immune responses - highlights from a new SPIE photonics west conference (BIOS 2006). Photodiag Photodyn Ther. 2006;3(3):184-9.
127. Konan-Kouakou YN, Boch R, Gurny R, Allemann E. In vitro and in vivo activities of verteporfin-loaded nanoparticles. J Control Release. 2005 Mar 2;103(1):83-91.
128. Lustig RA, Vogl TJ, Fromm D, Cuenca R, Hsi RA, D'Cruz AK, Krajina Z, Turi M, Singhal A, Chen JC. A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors. Cancer. 2003 October 15;98(8):1767-71.
129. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004 Sep 22;56(11):1649-59.
130. Winship M, Wang S, Chen J, Keltner L, Christophersen J. Treatment of colorectal liver metastases using talaporfin sodium and intratumoral placement of LEDs (Abstract). J Clin Oncol, 2005 ASCO Ann Proceed. 2005 June 1 Supplement;23(16S):3363.